Overview
Emmanuelle Trombe, Bertrand Delafaye, Marion Abecassis, Antoine Vergnat and Côme de Saint-Vincent provided corporate and tax advice to Innate Pharma on the acquisition of development and commercialization rights for the Anti-C5aR immuno-oncology antibody from Novo Nordisk A/S.